Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 12/20 | 0.47 |
| ▸ | CTSA | P10619 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5927547 | 0.97 | LRRK2 (0.47) | LRRK2LMNAALDH1A1MAPK1FFAR4 | |
| SCHEMBL5926827 | 0.97 | LRRK2 (0.47) | LRRK2LMNAALDH1A1MAPK1FFAR4 | |
| SCHEMBL5927061 | 0.97 | LRRK2 (0.50) | LRRK2CTSALMNAALDH1A1MAPK1 | |
| SCHEMBL5927121 | 0.94 | RXRA (0.46) | LRRK2LMNAALDH1A1MAPK1 | |
| SCHEMBL5927429 | 0.94 | LRRK2 (0.47) | LRRK2CTSALMNAALDH1A1MAPK1 | |
| SCHEMBL5926635 | 0.93 | MMP12 (0.49) | LRRK2LMNAALDH1A1MAPK1FFAR4 | |
| SCHEMBL3993208 | 0.92 | KIFC1 (0.45) | LRRK2CTSALMNAALDH1A1MAPK1 | |
| SCHEMBL3996604 | 0.92 | LRRK2 (0.45) | LRRK2LMNAALDH1A1MAPK1 | |
| SCHEMBL5926981 | 0.92 | PTGS2 (0.46) | LRRK2LMNAALDH1A1MAPK1 | |
| SCHEMBL5927500 | 0.90 | LRRK2 (0.51) | LRRK2CTSALMNAALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TFPI, F9, F2 | LRRK2 638/4885CTSA 426/4885LMNA 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.